Freudenberg strengthens medical technology sector

Weinheim, August 17, 2015. The Freudenberg Group continues to reinforce its technological competence in the medical sector. With immediate effect, the Freudenberg Medical Business Group has acquired a 75-percent stake in Hemoteq AG of Würselen, Germany. Freudenberg Medical therefore acquires the shares of the current shareholders Earlybird Venture Capital and Pinova Capital. Hemoteq AG is a world leader in coating technologies and services for medical technology products. "Through this partnership, we are extending our range of innovative combination products in the medical technology sector. The Freudenberg Medical Business Group continues to expand its broad portfolio," says Dr. Mohsen Sohi, Speaker of the Board of Management of the Freudenberg Group.

The remaining 25 percent of the shares in the company will continue to be held by its founders, Dr. Michael Hoffmann and Roland Horres. The two co-founders still form together with CFO Thomas Löwen the Directors Board of Hemoteq.

Freudenberg Medical is a global manufacturer of special components and systems for the medical technology and pharmaceutical industries. With patented processes, Hemoteq manufactures combination products such as drug-eluting stents and drug-coated balloons. In addition, Hemoteq develops and produces a wide variety of other innovative solutions for the surface functionalization of medical devices such as hydrophilic coatings for catheters or contact lens applicators. "Thanks to the combination of the material processing expertise of Freudenberg Medical and the leading coating technology of Hemoteq, customers will benefit from a unique portfolio of product solutions," says Dr. Jörg Schneewind, CEO of Freudenberg Medical. The services provided by Hemoteq range from the development and approval of medical devices through to series production. Freudenberg Medical already produces minimally invasive systems and special components from silicone, thermoplastic materials and metals with properties which can be optimized for medical technology applications by coating. Through these processing stages, Freudenberg Medical products support the innovations of its customers in the medical technology and pharmaceutical industries.

"Freudenberg Medical's excellent market access will provide Hemoteq AG with an opportunity to offer our solutions throughout the world. Thanks to the long-term orientation and financial stability of Freudenberg, our customers will benefit from reliable support during the long development processes and product life cycles in the medical technology sector," says Dr. Michael Hoffmann, CEO of Hemoteq AG.

About Freudenberg Medical

Freudenberg Medical is a leading global manufacturer of components for medical devices, complex catheter systems for minimally-invasive surgery and total solutions for the biotech, healthcare and pharmaceutical industries. In 2014, Freudenberg Medical generated sales of around €116 million from its sites in Asia, the USA and Central America as well as Europe with a workforce of some 1,000 employees.

About the Freudenberg Group

Freudenberg is a global technology group that strengthens its customers and society long-term through forward-looking innovations. Together with its partners, customers and the world of science, the Freudenberg Group develops leading-edge technologies, and excellent products, solutions and services for more than 30 market segments and for thousands of applications: seals, vibration control components, nonwovens, filters, specialty chemicals, medical and mechatronic products, IT services and the most modern cleaning products.

Innovation strength, strong customer orientation, diversity and team spirit are the cornerstones of our Group. Commitment to excellence, reliability and pro-active, responsible action belong to the company's core values lived for more than 165 years.

In 2014, the Freudenberg Group employed over 40,000 people in some 60 countries worldwide and generated sales of more than 7 billion Euros (including pro-rata consolidation of 50:50 joint ventures). For more information, please visit